emerging innovations in psychedelic healthcare

Thursday 17 November, 4.00pm - 7.30pm

Emerging Innovations in Psychedelic Healthcare

The psychedelic healthcare industry is expected to be worth US$5 billion by 2028

Emerging Innovations in Psychedelic Healthcare

On Thursday, 17 November, decision makers from across the ecosystem evaluated milestones in the adoption of psychedelic healthcare, through open panel discussions, fireside interviews and facilitated networking.

The event coincided with the release of the industry’s leading data and insights publication, The Psychedelics as Medicine Report: Fourth Edition.


* Fireside interview with Cybin’s CEO Doug Drysdale, on the future of psychedelic healthcare and investment.

* Panel discussion on ketamine, MDMA and psilocybin-assisted therapy market sizing, with Awakn’s CEO Anthony Tennyson, Small Pharma’s CEO George  Tziras and Cybin’s CEO Doug Drysdale.

* Fireside interview with Vadim Uzberg, Partner at Negev Capital, on market consolidation and the resulting commercial opportunities.

Date: 17 November
Time: 4.00pm – 7.30pm
Venue: Sea Containers, London

Presenting Companies

Awakn Life Sciences is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder.

Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognised scientists, on a mission to create safe and effective therapeutics for patients.

Negev Capital is a psychedelic medical intervention investment fund with assets of US$30 million. It invests in drug discovery with a focus on preclinical and Phase 1 development stages.

Looking for Exposure?

Apply to partner with PSYCH and showcase your organisation.
  • Participation in the panel discussion on market sizing and the future of investment
  • Present your company in a fireside interview with top-tier financial media
  • Brand inclusion in The Psychedelics As Medicine Report: Fourth Edition
  • A feature in The Psychedelic Newsletter - sent to 26000 subscribers
  • Two complimentary tickets and facilitated networking opportunities

Looking to Attend?

Invite only, please register your interest
  • Discover industry opportunities through exclusive market intelligence
  • Connect with CEOs from leading psychedelic healthcare companies
  • Network in an intimate setting of c50 attendees


The inaugural PSYCH Symposium was a sold out event, with decision makers converging to unlock the industry’s potential.

Europe’s leading psychedelic healthcare conference will return to London Spring 2023.